Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

BrainStorm Presentation on New Biomarker Data - NurOwn® at the 32nd International Symposium on ALS/MND

Brainstorm’s December 7, 2021 Presentation on new Biomarker data at the 32nd International Symposium on ALS/MND.

Corresponding Presentation

Recent News
Jul 1, 2024
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK, July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...

Jun 27, 2024
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a...

Jun 26, 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food...

View All

Events
Corporate Mid-Year Update on NurOwn Program
Monday, July 8, 2024
8:00am EDT

Investor dial in:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 358402

Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 50824

Press Release

View All

Email Alerts
Email Alerts
Investor Contact
Investor Contact
Investor FAQs
Investor FAQs
RSS Feeds
RSS Feeds
Investors